lenalidomide has been researched along with dinaciclib in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (dinaciclib) | Trials (dinaciclib) | Recent Studies (post-2010) (dinaciclib) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 133 | 12 | 129 |
| Protein | Taxonomy | lenalidomide (IC50) | dinaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0272 | |
| Cyclin-K | Homo sapiens (human) | 0.0227 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0162 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0742 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.049 | |
| Cyclin-A2 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.119 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.0028 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0074 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.23 | |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | 0.0039 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.414 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.324 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.1273 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0227 | |
| Cyclin-H | Homo sapiens (human) | 0.17 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.17 | |
| Cyclin-A1 | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.011 | |
| Heat shock factor protein 1 | Homo sapiens (human) | 0.007 | |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.0219 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 0.0323 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Moreau, P; Rajkumar, SV | 1 |
1 review(s) available for lenalidomide and dinaciclib
| Article | Year |
|---|---|
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
1 other study(ies) available for lenalidomide and dinaciclib
| Article | Year |
|---|---|
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |